Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII

• Published in: Lupus Vol. 33; no. 10; pp. 1109 - 1115
• Main Authors: Zhao, Man, Ma, Leyao, Duan, Xinwang, Huo, Yuehong, Liu, Shengyun, Zhao, Cheng, Zheng, Zhaohui, Wang, Qian, Tian, Xinping, Chen, Yunzhuan, Li, Mengtao
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.09.2024; Sage Publications Ltd
• Subjects: Adverse events; Autoimmune diseases; Cohort analysis; Lesions; Lupus; Patients; Remission; Serology; Systemic lupus erythematosus; Thalidomide; systemic lupus erythematosus; Tofacitinib; thalidomide; mucocutaneous lesions

Objective Thalidomide is an effective medication for refractory mucocutaneous lesions of systemic lupus erythematosus (SLE) and can treat arthritis in some autoimmune diseases, but it has some adverse reactions. Recently, the effectiveness of tofacitinib in treating mucocutaneous lesions of SLE has...